Patents by Inventor Rien van Haperen

Rien van Haperen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SARS-COV-2(SARS2, COVID-19) ANTIBODIES
    Publication number: 20220017606
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. in some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection, In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).
    Type: Application
    Filed: July 20, 2021
    Publication date: January 20, 2022
    Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien Van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
  • ANTIBODIES BINDING CTLA-4 AND USES THEREOF
    Publication number: 20220002414
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 6, 2022
    Applicant: Harbour BioMed (Shanghai) Co., Ltd.
    Inventors: Xin GAN, Yun HE, Yuqiang SHEN, Jiuqiao ZHAO, Yiping RONG, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens
  • SARS-COV-2 (SARS2, COVID-19) ANTIBODIES
    Publication number: 20210340225
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).
    Type: Application
    Filed: March 5, 2021
    Publication date: November 4, 2021
    Inventors: Franklin Gerardus Grosveld, Dubravka Drabek, Rien van Haperen, Berend Jan Bosch, Juliette Fedry, Daniel L. Hurdiss, Thijs Kuiken, Batholomeus Leonardus Haagmans, Barry Hubertus Gerardus Rockx
  • Antibodies binding CTLA-4 and uses thereof
    Patent number: 11098122
    Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 24, 2021
    Assignee: HARBOUR BIOMED (SHANGHAI) CO., LTD.
    Inventors: Xin Gan, Yun He, Yuqiang Shen, Jiuqiao Zhao, Yiping Rong, Frank Grosveld, Dubravka Drabek, Marinus (Rien) Van Haperen, Rick Janssens